6.96

4.00% -0.29

After Hours: 6.99 0.03 +0.43%

Ginkgo Bioworks Holdings Inc (DNA)

Overview News Price History Option Chain Why DNA Down? Discussions Forecast

Ginkgo Bioworks Holdings Inc stock is traded at $6.96, with a volume of 655.75K. It is down -4.00% in the last 24 hours and down -5.56% over the past month. Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering: where company provide biological R&D services for customers across a range of industries and Biosecurity: where it provide services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.

Previous Close:

$7.25

Open:

$7.12

24h Volume:

655.75K

Relative Volume:

0.50

Market Cap:

$322.60M

Revenue:

$217.11M

Net Income/Loss:

$-651.19M

P/E Ratio:

-0.5358

EPS:

-12.99

Net Cash Flow:

$-387.26M

1W Performance:

-0.43%

1M Performance:

-5.56%

6M Performance:

-20.00%

1Y Performance:

-68.89%

1-Day Range:

$6.90

$7.17

1-Week Range:

$6.755

$7.62

52-Week Range:

$5.00

$23.24

Ginkgo Bioworks Holdings Inc Stock (DNA) Company Profile

Name

Ginkgo Bioworks Holdings Inc

Sector

Healthcare (1178)

Industry

Biotechnology (671)

Phone

(877) 442-5362

Address

27 DRYDOCK AVENUE, BOSTON

Employee

834

Twitter

Next Earnings Date

2024-08-08

Latest SEC Filings

DNA's Discussions on Twitter

Compare DNA with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
DNA Ginkgo Bioworks Holdings Inc	6.96	400.94M	217.11M	-651.19M	-387.26M	-12.99
ONC Beone Medicines Ltd Adr	245.58	25.81B	3.81B	-644.79M	-669.77M	-6.24
VRTX Vertex Pharmaceuticals Inc	441.85	111.46B	11.10B	-988.90M	-1.26B	-3.92
AKTX Akari Therapeutics Plc Adr	1.35	40.37M	0	0	0	0.00
VRNA Verona Pharma Plc Adr	81.16	6.19B	0	-153.72M	-103.81M	-2.00
REGN Regeneron Pharmaceuticals Inc	489.52	64.44B	14.09B	4.50B	2.96B	39.28

Ginkgo Bioworks Holdings Inc Stock (DNA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
May-15-24	Downgrade	BTIG Research	Neutral → Sell
May-10-24	Downgrade	William Blair	Mkt Perform → Underperform
Nov-14-23	Downgrade	Raymond James	Outperform → Mkt Perform
Nov-09-23	Downgrade	BTIG Research	Buy → Neutral
Jun-02-23	Downgrade	Goldman	Neutral → Sell
May-11-23	Downgrade	William Blair	Outperform → Mkt Perform
Nov-29-22	Initiated	Berenberg	Buy
Oct-04-22	Initiated	Morgan Stanley	Equal-Weight
May-18-22	Downgrade	BofA Securities	Neutral → Underperform
Mar-02-22	Resumed	Cowen	Outperform
Feb-23-22	Initiated	Goldman	Neutral
Feb-01-22	Initiated	BofA Securities	Neutral
Jan-28-22	Initiated	BofA Securities	Buy
Jan-07-22	Initiated	BTIG Research	Buy
Nov-29-21	Initiated	Jefferies	Buy
Oct-13-21	Initiated	Raymond James	Outperform
Oct-12-21	Initiated	William Blair	Outperform
Sep-20-21	Initiated	HSBC Securities	Buy

View All

Ginkgo Bioworks Holdings Inc Stock (DNA) Latest News

May 28, 2025

(DNA) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com

May 28, 2025

May 27, 2025

Ginkgo Bioworks Partners with HaDEA in Up to €24 Million Consortium Project to Deliver Next-Generation 'Agnostic Diagnostics' for Respiratory Viruses at the Point of Care - Quantisnow

May 27, 2025

May 22, 2025

Ginkgo Bioworks CFO Mark Dmytruk to Resign, Steven Coen Appointed as New Finance Chief - marketscreener.com

May 21, 2025

Ginkgo Bioworks Announces Appointment Of Steven Coen As Chief Financial Officer - marketscreener.com

May 21, 2025

Charles River Laboratories (CRL): Leadership Change at Ginkgo Bi - GuruFocus

May 21, 2025

Charles River Laboratories (CRL): Leadership Change at Ginkgo Bioworks | CRL Stock News - GuruFocus

May 21, 2025

Ginkgo Bioworks Announces Appointment of Steven Coen as Chief Financial Officer - StreetInsider

May 21, 2025

Ginkgo Bioworks Promotes 30-Year Finance Expert to CFO Role, Maintains 2026 EBITDA Target - Stock Titan

May 21, 2025

May 19, 2025

Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) is a favorite amongst institutional investors who own 56% - Yahoo Finance

May 19, 2025

May 17, 2025

When the Price of (DNA) Talks, People Listen - news.stocktradersdaily.com

May 17, 2025

May 14, 2025